COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study
Yıl: 2023 Cilt: 5 Sayı: 2 Sayfa Aralığı: 127 - 135 Metin Dili: İngilizce DOI: 10.36519/idcm.2023.192 İndeks Tarihi: 05-07-2023
COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study
Öz: Objective: Psoriasis patients may have been affected by COVID-19 differently than the nor- mal population due to using different types of treatments, including immunosuppressive agents and biological therapies, the probability of lower effectiveness, and different side effects of the vaccines. This study aimed to evaluate the epidemiologic and clinical features of COVID-19 and the effect of the psoriasis treatment on it. Materials and Methods: Psoriasis patients followed up in our clinic between March 2020 and July 2022 were evaluated in terms of clinicodemographic characteristics, treatment methods, and COVID-19 vaccination status and compared regarding COVID-19 history. Results: A total of 110 patients (female:male ratio=1:1.2) with a mean age of 45.6±14.3 years were evaluated. Thirty patients (27.2%) developed COVID-19 during psoriasis treatment. Unvaccinated patients had COVID-19 (6/11, 55%) more frequently than vaccinated ones (24/99, 24%), but it was not statistically significant (p =0.067). Although patients who re- ceived biological therapy were also more frequently infected with SARS-CoV-2 than pa- tients who received other types of therapies (18/53 [34%] versus 12/57 [21%], respectively), the difference was again not statistically significant. A patient with hypertension using acitretin was hospitalized for pulmonary involvement because of COVID-19. No exacerba- tion of psoriasis was observed in patients who developed COVID-19, while psoriasis flares occurred following COVID-19 mRNA vaccination in two patients. Conclusion: Patients with psoriasis should get vaccinated against COVID-19, as vaccination prevents the disease and does not result in serious side effects. Although using biological agents for the treatment of psoriasis could be related to a higher risk of getting COVID-19, these agents do not increase the risk of severe COVID-19. Therefore, they may be beneficial in reducing the risk of both psoriasis exacerbations and severe COVID-19 due to the cy- tokine storm among patients using biological for psoriasis. However, large-scale and con- trolled studies are needed to support our conclusions.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1 Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. [CrossRef]
- 2 Elmas ÖF, Demirbaş A, Kutlu Ö, Bağcıer F, Metin MS, Özyurt K, et al. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol Ther. 2020;33(6):e13858. [CrossRef]
- 3 Kamiya K, Komine M, Ohtsuki M. Biologics for psoriasis during the COVID-19 pandemic. J Clin Med. 2021;10(7):1390. [Cross- Ref]
- 4 Abo-Tabik M, Parisi R, Willis SC, Griffiths CEM, Ashcroft DM; Global Psoriasis Atlas (GPA). Development of clinical diagnos- tic criteria for chronic plaque psoriasis: an international e-Del- phi study. Br J Dermatol. 2021;185(2):455-6. [CrossRef]
- 5 Yiu ZZN, Harding-Oredugba G, Griffiths CEM, Warren RB, Mc- Mullen E, Hunter HJA. Risk of COVID-19 infection in adult patients with atopic eczema and psoriasis: a single-centre cross-sectional study. Br J Dermatol. 2021;185(2):441-3. [Cross- Ref]
- 6 Tan EH, Sena AG, Prats-Uribe A, You SC, Ahmed WU, Kostka K, et al. COVID-19 in patients with autoimmune diseases: charac- teristics and outcomes in a multinational network of cohorts across three countries. Rheumatology (Oxford). 2021;60(SI):- SI37-SI50. [CrossRef]
- 7 Tembhre MK, Parihar AS, Sharma VK, Imran S, Bhari N, Lakshmy R, et al. Enhanced expression of angiotensin-con- verting enzyme 2 in psoriatic skin and its upregulation in kera- tinocytes by interferon-γ: implication of inflammatory milieu in skin tropism of SARS-CoV-2. Br J Dermatol. 2021;184(3):577- 9. [CrossRef]
- 8 Zeng H, Wang S, Chen L, Shen Z. Biologics for Psoriasis During the COVID-19 Pandemic. Front Med (Lausanne). 2021;8:759568. [CrossRef]
- 9 Gisondi P, Zaza G, Del Giglio M, Rossi M, Iacono V, Girolomo- ni G. Risk of hospitalization and death from COVID-19 in- fection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in main- tenance immunosuppressive treatment. J Am Acad Dermatol. 2020;83(1):285-7. [CrossRef]
- 10 Kridin K, Schonmann Y, Damiani G, Peretz A, Onn E, Bitan DT, et al. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in pa- tients with psoriasis-A population-based cohort study. Derma- tol Ther. 2021;34(4):e15003. [CrossRef]
- 11 Amerio P, Prignano F, Giuliani F, Gualdi G. COVID-19 and pso- riasis: Should we fear for patients treated with biologics? Der- matol Ther. 2020;33(4):e13434. [CrossRef]
- 12 Conti A, Lasagni C, Bigi L, Pellacani G. Evolution of COVID-19 infection in four psoriatic patients treated with biological drugs. J Eur Acad Dermatol Venereol. 2020;34(8):360-1. [CrossRef]
- 13 Wack S, Patton T, Ferris LK. COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence. J Am Acad Dermatol. 2021;85(5):1274-84. [CrossRef]
- 14 Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Cal- abrese C, et al. National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease man- agement, COVID-19 vaccines, and COVID-19 treatments. J Am Acad Dermatol. 2021;84(5):1254-68. [CrossRef]
- 15 Wang J, Peng Y, Xu H, Cui Z, Williams RO 3rd. The COVID-19 vaccine Race: Challenges and opportunities in vaccine formu- lation. AAPS PharmSciTech. 2020;21(6):225. [CrossRef]
- 16 Park JK, Lee YJ, Shin K, Ha YJ, Lee EY, Song YW, et al. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2018;77(6):898-904. [CrossRef]
- 17 Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J, et al; VROOM study investigators. Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial. Lancet Respir Med. 2022;10(9):840- 50. [CrossRef]
- 18 El-Qushayri AE, Nardone B. Psoriasis exacerbation after COVID-19 vaccines: A brief report of the reported cases. Der- matol Ther. 2022;35(12):e15900. [CrossRef]
- 19 Gunes AT, Fetil E, Akarsu S, Ozbagcivan O, Babayeva L. Possible triggering Effect of Influenza Vaccination on Psoriasis. J Immu- nol Res. 2015;2015:258430. [CrossRef]
- 20 Wang Q, Lv C, Han X, Shen M, Kuang Y. A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS- CoV-2 Vaccines in Chinese Patients with Psoriasis. J Inflamm Res. 2021 Nov 27;14:6265-73. [CrossRef]
- 21 McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol. 2021;85(1):46-55. [CrossRef]
- 22 Mathieu RJ, Cobb CBC, Telang GH, Firoz EF. New-onset pustular psoriasis in the setting of severe acute respiratory syndrome coronavirus 2 infection causing coronavirus disease 2019. JAAD Case Rep. 2020;6(12):1360-2. [CrossRef]
- 23 Rouai M, Rabhi F, Mansouri N, Jaber K, Dhaoui R. New-on- set guttate psoriasis secondary to COVID-19. Clin Case Rep. 2021;9(7):e04542. [CrossRef]
- 24 Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840-8. [Cross- Ref]
- 25 Thakur B, Dubey P, Benitez J, Torres JP, Reddy S, Shokar N, et al. A systematic review and meta-analysis of geographic differ- ences in comorbidities and associated severity and mortality among individuals with COVID-19. Sci Rep. 2021;11(1):8562. [CrossRef]
- 26 Shahidi-Dadras M, Tabary M, Robati RM, Araghi F, Dadkhah- far S. Psoriasis and risk of the COVID-19: is there a role for angiotensin converting enzyme (ACE)? J Dermatolog Treat. 2022;33(2):1175-6. [CrossRef]
- 27 Pesqué D, Lopez-Trujillo E, Marcantonio O, Giménez-Arnau AM, Pujol RM. New-onset and exacerbations of psoriasis after mRNA COVID-19 vaccines: two sides of the same coin? J Eur Acad Dermatol Venereol. 2022;36(2):80-1. [CrossRef]
| APA | KAYA O, KESKİNKAYA Z, ışık mermutlu s, OGUZ KILIÇ S, ÇAKIR H (2023). COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. , 127 - 135. 10.36519/idcm.2023.192 |
| Chicago | KAYA OZGE,KESKİNKAYA ZEYNEP,ışık mermutlu selda,OGUZ KILIÇ SEVİLAY,ÇAKIR Haile COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. (2023): 127 - 135. 10.36519/idcm.2023.192 |
| MLA | KAYA OZGE,KESKİNKAYA ZEYNEP,ışık mermutlu selda,OGUZ KILIÇ SEVİLAY,ÇAKIR Haile COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. , 2023, ss.127 - 135. 10.36519/idcm.2023.192 |
| AMA | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. . 2023; 127 - 135. 10.36519/idcm.2023.192 |
| Vancouver | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. . 2023; 127 - 135. 10.36519/idcm.2023.192 |
| IEEE | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H "COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study." , ss.127 - 135, 2023. 10.36519/idcm.2023.192 |
| ISNAD | KAYA, OZGE vd. "COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study". (2023), 127-135. https://doi.org/10.36519/idcm.2023.192 |
| APA | KAYA O, KESKİNKAYA Z, ışık mermutlu s, OGUZ KILIÇ S, ÇAKIR H (2023). COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. Infectious diseases and clinical microbiology (Online), 5(2), 127 - 135. 10.36519/idcm.2023.192 |
| Chicago | KAYA OZGE,KESKİNKAYA ZEYNEP,ışık mermutlu selda,OGUZ KILIÇ SEVİLAY,ÇAKIR Haile COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. Infectious diseases and clinical microbiology (Online) 5, no.2 (2023): 127 - 135. 10.36519/idcm.2023.192 |
| MLA | KAYA OZGE,KESKİNKAYA ZEYNEP,ışık mermutlu selda,OGUZ KILIÇ SEVİLAY,ÇAKIR Haile COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. Infectious diseases and clinical microbiology (Online), vol.5, no.2, 2023, ss.127 - 135. 10.36519/idcm.2023.192 |
| AMA | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. Infectious diseases and clinical microbiology (Online). 2023; 5(2): 127 - 135. 10.36519/idcm.2023.192 |
| Vancouver | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study. Infectious diseases and clinical microbiology (Online). 2023; 5(2): 127 - 135. 10.36519/idcm.2023.192 |
| IEEE | KAYA O,KESKİNKAYA Z,ışık mermutlu s,OGUZ KILIÇ S,ÇAKIR H "COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study." Infectious diseases and clinical microbiology (Online), 5, ss.127 - 135, 2023. 10.36519/idcm.2023.192 |
| ISNAD | KAYA, OZGE vd. "COVID-19 Among Patients with Psoriasis: A Single-Center Retrospective Cross-Sectional Study". Infectious diseases and clinical microbiology (Online) 5/2 (2023), 127-135. https://doi.org/10.36519/idcm.2023.192 |
